This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Febantel
DrugBank Accession Number
DB11409
Background

Not Available

Type
Small Molecule
Groups
Experimental, Vet approved
Structure
Thumb
Weight
Average: 446.48
Monoisotopic: 446.126005618
Chemical Formula
C20H22N4O6S
Synonyms
  • Febantel
  • Febantelum
External IDs
  • BAY H 5757
  • BAY VH 5757
  • BAY Vh5757

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Negabot Plus Paste / Oratel / Rintal

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diarylthioethers. These are organosulfur compounds containing a thioether group that is substituted by two aryl groups.
Kingdom
Organic compounds
Super Class
Organosulfur compounds
Class
Thioethers
Sub Class
Aryl thioethers
Direct Parent
Diarylthioethers
Alternative Parents
Anilides / Thiophenol ethers / N-arylamides / Methylcarbamates / Guanidines / Secondary carboxylic acid amides / Organic carbonic acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Sulfenyl compounds / Dialkyl ethers
show 6 more
Substituents
Anilide / Aromatic homomonocyclic compound / Benzenoid / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Carboxamide group / Carboximidamide / Carboxylic acid derivative / Dialkyl ether
show 19 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
S75C401OS1
CAS number
58306-30-2
InChI Key
HMCCXLBXIJMERM-UHFFFAOYSA-N
InChI
InChI=1S/C20H22N4O6S/c1-28-12-17(25)21-16-11-14(31-13-7-5-4-6-8-13)9-10-15(16)22-18(23-19(26)29-2)24-20(27)30-3/h4-11H,12H2,1-3H3,(H,21,25)(H2,22,23,24,26,27)
IUPAC Name
methyl N-{[(methoxycarbonyl)amino]({[2-(2-methoxyacetamido)-4-(phenylsulfanyl)phenyl]imino})methyl}carbamate
SMILES
COCC(=O)NC1=C(C=CC(SC2=CC=CC=C2)=C1)N=C(NC(=O)OC)NC(=O)OC

References

General References
  1. Thomas H: Ovacidal activity of febantel. N Z Vet J. 1979 Dec;27(12):273-5. [Article]
  2. Ben-Zvi Z, Gussarsky E, van Creveld C, Yagil R: The bioavailability of febantel in dehydrated camels. J Vet Pharmacol Ther. 1996 Aug;19(4):288-94. [Article]
  3. Wollweber H, Kolling H, Widdig A, Thomas H, Schulz HP, Murmann P: Febantel, a new broad-spectrum anthelminthic. Arzneimittelforschung. 1978;28(12):2193-5. [Article]
  4. Blagburn BL, Hendrix CM, Hanrahan LA, Lindsay DS, Arther RG, Drane JW: Controlled dosage titration of febantel paste in naturally parasitized cattle. Am J Vet Res. 1989 Sep;50(9):1574-7. [Article]
  5. Corwin RM, Pratt SE, McCurdy HD: Anthelmintic effect of febantel/praziquantel paste in dogs and cats. Am J Vet Res. 1984 Jan;45(1):154-5. [Article]
  6. Stuedemann JA, Ciordia H, Arther RG: Anthelmintic efficacy of febantel paste in naturally infected calves. Vet Parasitol. 1990 Apr;35(4):341-7. [Article]
  7. Sharp ML, McCurdy HD: Anthelmintic efficacy of febantel combined with praziquantel in dogs. J Am Vet Med Assoc. 1985 Aug 1;187(3):254-5. [Article]
  8. Williams JC, Marbury KS, Eddi CS, Willis ER, Luther DG: Efficacy of febantel against abomasal nematodes and lungworms in cattle. Am J Vet Res. 1988 Dec;49(12):2085-9. [Article]
  9. Ciordia H, McCampbell HC, Stuedemann JA: Anthelmintic efficacy of febantel against gastrointestinal helminths in calves. Am J Vet Res. 1982 Dec;43(12):2248-9. [Article]
  10. Hagan CJ: More on febantel and trichlorfon. Vet Med Small Anim Clin. 1979 Jan;74(1):6. [Article]
KEGG Drug
D04135
ChemSpider
4514715
BindingDB
50103610
RxNav
24805
ChEMBL
CHEMBL1080983
ZINC
ZINC000004215999

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0052 mg/mLALOGPS
logP2.73ALOGPS
logP3.17ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)9.48ChemAxon
pKa (Strongest Basic)-2.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area127.35 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity118.27 m3·mol-1ChemAxon
Polarizability45.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at February 25, 2016 18:28 / Updated at February 21, 2021 18:53